Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagno...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Cancer J
Главные авторы: Schmidt, Timothy M., Barwick, Benjamin G., Joseph, Nisha, Heffner, Leonard T., Hofmeister, Craig C., Bernal, Leon, Dhodapkar, Madhav V., Gupta, Vikas A., Jaye, David L., Wu, Jiayi, Goyal, Subir, Chen, Zhengjia, Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K., Kaufman, Jonathan L.
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877577/
https://ncbi.nlm.nih.gov/pubmed/31767829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0254-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы